Home › Compare › CSSXF vs ABBV
CSSXF yields 6666.67% · ABBV yields 3.12%● Live data
📍 CSSXF pulled ahead of the other in Year 1
Combined, CSSXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSSXF + ABBV for your $10,000?
China Shuifa Singyes Energy Holdings Limited, an investment holding company, designs, fabricates, and installs conventional curtain walls and solar projects in Mainland China, Oceania, Macau, Malaysia, Hong Kong, and internationally. Its solar projects include building integrated photovoltaic systems, roof top solar systems, and ground mounted solar systems. The company also manufactures and sells renewable energy goods, including smart grid systems; solar thermal systems and products, such as air-source heat pumps, flat-pane solar thermal collectors, photovoltaic and photothermal composite modules, and absorbing coating products; smart LCD dimming films; smart LCD dimming glass products; and indium-tin oxide films. In addition, it engages in the development of new energy materials and marine biology technology; research and development of energy- saving products; research and development of electricity and new energy; provision of engineering design services; and research, construction, and operation of solar power station. The company was formerly known as China Singyes Solar Technologies Holdings Limited and changed its name to China Shuifa Singyes Energy Holdings Limited in April 2020. China Shuifa Singyes Energy Holdings Limited was founded in 1995 and is headquartered in Central, Hong Kong.
Full CSSXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.